NYU developing HIV antibodies and RNA test in a single POC

March 27, 2015

New York University College of Dentistry (NYUCD) has received a sub-award in the amount of $335,000 from a Small Business Innovation Research (SBIR) Phase II grant from the National Institutes of Health (NIH) to complete the development of a fully automated self-confirming assay that can simultaneously detect HIV/AIDS antibodies and viral RNA from the AIDS virus in a single specimen.

The $1.5M Phase II grant was awarded to Rheonix, Inc., an Ithaca, New York-based medical technology company, specializing in making automated and highly customizable molecular diagnostic devices. The NYUCD portion of the grant is led by Dr. Daniel Malamud, professor of basic science and craniofacial biology and director of the HIV/AIDS Research Program at NYUCD.

"Current HIV corroborative testing requires considerable time and cost, and is often not available in remote geographic areas," said Dr. Malamud. "As a result, many individuals with a positive antibody screening test opt out of taking the corroborative test. Our research aims to address this problem through the development of an affordable, easy to use point-of-care (POC) test, capable of detecting pathogen nucleic acids and antibodies to the pathogens in less than one hour.

Working with Rheonix, Dr. Malamud and his team utilize a Rheonix CARD® cartridge system: a simple disposable card that acts as a receptacle for blood or saliva samples. The card is then placed on an instrument that carries out all of the required steps in processing the sample. Within seven minutes, one part of the sample runs out onto a strip to detect HIV antibodies, while another portion of the samples undergoes isolation of nucleic acid and amplification using LAMP, an isothermal process. The entire testing process takes less than one hour, is mobile, and can be battery operated.

"In order to get approval, you need to prove that you're as good as the existing commercial equivalent," explains Dr. Malamud. "We have proof that our system works, but we have tested hundreds of samples and we need thousands."

"I'm reasonably confident that within 18 months we will have a finished product, which will allow an individual to simply collect a sample, insert it into the CARD, push a button, and, within one hour, have an accurate test result," says Dr. Malamud.
-end-
About New York University College of Dentistry: New York University College of Dentistry (NYUCD) is the third oldest and the largest dental school in the US, educating more than 8 percent of all dentists. NYUCD has a significant global reach and provides a level of national and international diversity among its students that is unmatched by any other dental school. http://www.nyu.edu/dental/

About Rheonix, Inc.: Rheonix Inc. is committed to improving standards of care by making molecular diagnostics available to more people, in more places, more often. Rheonix, through experienced leadership and creative vision, has developed the EncompassMDx® platform, a highly customizable technology with unmatched versatility and affordability. The platform performs fully automated, complex molecular assays in an easy-to-use and economical format on the Rheonix CARD® cartridge. With both the Rheonix CARD and EncompassMDx family of products, Rheonix is well-positioned to penetrate key molecular diagnostic market sectors, from reference labs through point-of-care and everywhere in between. For more information, visit http://www.rheonix.com.

New York University

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.